# Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012

> **NCT02579681** · PHASE3 · COMPLETED · sponsor: **Biogen** · enrollment: 221 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **DRUG:** dimethyl fumarate

## Key facts

- **NCT ID:** NCT02579681
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-30
- **Primary completion:** 2016-12-21
- **Final completion:** 2016-12-21
- **Target enrollment:** 221 (ACTUAL)
- **Last updated:** 2017-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02579681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02579681, "Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02579681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*